COVID-19 vaccines versus pediatric hospitalization

[1]  H. So,et al.  Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong , 2023, Communications Medicine.

[2]  N. Pearce,et al.  Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period , 2022, Nature Communications.

[3]  A. Cook,et al.  Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age , 2022, The New England journal of medicine.

[4]  A. Palamara,et al.  Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022 , 2022, The Lancet.

[5]  M. Hernán,et al.  BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age , 2022, The New England journal of medicine.

[6]  M. Peiris,et al.  Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents , 2022, Nature Communications.

[7]  J. Chan,et al.  Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections , 2022, Emerging microbes & infections.

[8]  E. Undurraga,et al.  Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile , 2022, Nature Medicine.

[9]  L. Abu-Raddad,et al.  Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization , 2022, Vaccine.

[10]  E. Estenssoro,et al.  Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.

[11]  Manish M Patel,et al.  BNT162b2 Protection against the Omicron Variant in Children and Adolescents , 2022, The New England journal of medicine.

[12]  Andrew L. Phillips,et al.  Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[13]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[14]  M. Lipsitch,et al.  Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study , 2021, The Lancet Infectious Diseases.

[15]  John Adams.  Assessing , 2020, Transport Planning.